cabazitaxel
Oncologists say CDF cuts will compromise treatment
March 10, 2015Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3
Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Sanofi prostate cancer drug Jevtana approved in Europe
March 21, 2011Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer
Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …
Sanofi’s Plavix combination recommended for European approval
December 21, 2009Research and Development, Sales and Marketing DuoPlavin, Plavix, Sanofi, cabazitaxel, eplivanserin, idrabiotaparinux
Sanofi-Aventis has received the backing of a key European regulatory committee for its cardiology treatment DuoPlavin, which combines its blockbuster …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
